Integra LifeSciences Holdings (Nasdaq: IART) is expected to report Q2 earnings on July 26. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Integra LifeSciences Holdings' revenues will expand 6.2% and EPS will compress -1.4%.

The average estimate for revenue is $205.4 million. On the bottom line, the average EPS estimate is $0.69.

Revenue details
Last quarter, Integra LifeSciences Holdings logged revenue of $196.2 million. GAAP reported sales were 8.4% higher than the prior-year quarter's $181.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.71. GAAP EPS of $0.23 for Q1 were 39% lower than the prior-year quarter's $0.38 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 64.3%, 60 basis points worse than the prior-year quarter. Operating margin was 13.6%, 130 basis points worse than the prior-year quarter. Net margin was 3.4%, 290 basis points worse than the prior-year quarter.

Looking ahead
The full year's average estimate for revenue is $829.8 million. The average EPS estimate is $3.02.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 159 members out of 169 rating the stock outperform, and 10 members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give Integra LifeSciences Holdings a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $38.23.

The healthcare investing landscape is littered with also-rans and a few major winners. Is Integra LifeSciences Holdings performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.